Favorable Regulatory Path

The Phase 3 result becomes the foundation for U.S. and European filings for the Roche-Ionis kidney drug, likely in IgA nephropathy or a closely related proteinuric kidney indication. The most likely path is positive regulatory engagement, though the breadth of the label depends on durability, eGFR data and safety detail.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.